ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 188 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2015. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2019 | $1,440,000 | +7.7% | 40,000 | -20.0% | 0.73% | +125.1% |
Q2 2019 | $1,337,000 | +84.9% | 50,000 | +5.6% | 0.32% | +16.2% |
Q2 2018 | $723,000 | -63.1% | 47,351 | -27.2% | 0.28% | -61.7% |
Q4 2017 | $1,957,000 | -56.7% | 65,000 | -45.8% | 0.73% | -52.8% |
Q3 2017 | $4,520,000 | +194.7% | 120,000 | +118.2% | 1.54% | +174.2% |
Q2 2017 | $1,534,000 | -31.4% | 55,000 | -15.4% | 0.56% | -46.1% |
Q1 2017 | $2,235,000 | +10.7% | 65,000 | -7.1% | 1.04% | +8.1% |
Q4 2016 | $2,019,000 | -3.2% | 70,000 | +6.7% | 0.96% | -8.5% |
Q3 2016 | $2,086,000 | +11.8% | 65,577 | +14.0% | 1.05% | +13.4% |
Q2 2016 | $1,866,000 | -33.3% | 57,500 | -42.5% | 0.93% | -25.0% |
Q1 2016 | $2,796,000 | +30.7% | 100,000 | +66.7% | 1.24% | +21.9% |
Q4 2015 | $2,139,000 | +14.9% | 60,000 | +6.5% | 1.02% | +12.5% |
Q3 2015 | $1,862,000 | -11.1% | 56,314 | +12.6% | 0.90% | +24.2% |
Q2 2015 | $2,094,000 | +83.5% | 50,000 | +42.9% | 0.73% | +87.4% |
Q1 2015 | $1,141,000 | – | 35,000 | – | 0.39% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |